Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | DDO | Q99489 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516976 | 0.84 | MCL1 (0.44) | ALDH1A1MAPTKDM4EDAO | |
| Urea SCHEMBL27364794 | 0.81 | AHR (0.41) | PARP1ALDH1A1MAPTDAOMET | |
| SCHEMBL7641382 | 0.76 | NR4A2 (0.41) | PARP1ALDH1A1MAPTDAOMET | |
| SCHEMBL4493831 | 0.75 | MAP2 (0.60) | MAP2ALDH1A1MAPTKDM4EDAO | |
| SCHEMBL20886859 | 0.72 | CYP1A2 (0.41) | PARP1ALDH1A1KDM4EDAODDO | |
| SCHEMBL1921411 | 0.71 | AHR (0.50) | PARP1MAPTKDM4EDAOGPR84 | |
| Urea SCHEMBL27376718 | 0.71 | BTK (0.39) | ALDH1A1MAPTKDM4EMETHSD17B10 | |
| SCHEMBL19639028 | 0.71 | DAO (0.47) | PARP1ALDH1A1MAPTKDM4EDAO | |
| SCHEMBL8796482 | 0.70 | PIM1 (0.46) | MAP2ALDH1A1MAPTKDM4EHSD17B10 | |
| SCHEMBL9435028 | 0.70 | MAP2 (0.47) | MAP2ALDH1A1MAPTKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479558-B2 | Substituted tetrahydropyranoindoles, derivatives thereof, and their methods of synthesis and use | NORTHWESTERN UNIVERSITY (US) | 2022-10-25 | — | — | US | disclosed |
| EP-3044207-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015036412-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-19 | — | — | WO | disclosed |
| EP-1171428-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-09-15 | — | — | EP | disclosed |
| EP-1171428-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063187-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479558-B2 | Substituted tetrahydropyranoindoles, derivatives thereof, and their methods of synthesis and use | HPGDS, SYVN1, PTGIS | MAP2 3693/4885PARP1 1015/4885ALDH1A1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.